Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
Adult
Allergens
/ immunology
Antigens, Plant
/ immunology
Conjunctivitis, Allergic
/ immunology
Desensitization, Immunologic
/ methods
Double-Blind Method
Female
Follow-Up Studies
Humans
Injections, Intralymphatic
Male
Placebo Effect
Poaceae
/ immunology
Pollen
/ immunology
Rhinitis, Allergic
/ immunology
Severity of Illness Index
Treatment Outcome
Allergic rhinoconjunctivitis
allergen immunotherapy
combined symptom medication score
intralymphatic immunotherapy
outcome parameters
ultrasound-guided injections
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
07
02
2020
revised:
30
06
2020
accepted:
02
07
2020
pubmed:
18
7
2020
medline:
23
9
2021
entrez:
18
7
2020
Statut:
ppublish
Résumé
Allergic rhinoconjunctivitis is a global health problem. Different allergen immunotherapy regimes are marketed but have low adherence because they are expensive, complex, and time-consuming. New allergen immunotherapy forms are needed. In a 3-year follow-up double-blind randomized placebo-controlled trial, we aimed to investigate the effect of intralymphatic allergen immunotherapy (ILIT). Patients with grass pollen rhinoconjunctivitis were treated with 3 ILIT injections and an ILIT booster 1 year later, 3 ILIT injections and a placebo booster, or 3 placebo injections and a placebo booster. Primary outcome was improvement in a combined symptom and medication score (cSMS). A novel evaluation tool with a linear regression model of cSMS and grass pollen counts was developed. Secondary outcomes were changes in grass specific immunoglobulins and skin and nasal provocation tests to grass pollen. A total of 36 patients were included. Log ILIT gives a substantial reduction in grass pollen allergy symptoms and use of rescue medication, significant in the first season after treatment. A booster injection had no additional effect.
Sections du résumé
BACKGROUND
Allergic rhinoconjunctivitis is a global health problem. Different allergen immunotherapy regimes are marketed but have low adherence because they are expensive, complex, and time-consuming. New allergen immunotherapy forms are needed.
OBJECTIVE
In a 3-year follow-up double-blind randomized placebo-controlled trial, we aimed to investigate the effect of intralymphatic allergen immunotherapy (ILIT).
METHODS
Patients with grass pollen rhinoconjunctivitis were treated with 3 ILIT injections and an ILIT booster 1 year later, 3 ILIT injections and a placebo booster, or 3 placebo injections and a placebo booster. Primary outcome was improvement in a combined symptom and medication score (cSMS). A novel evaluation tool with a linear regression model of cSMS and grass pollen counts was developed. Secondary outcomes were changes in grass specific immunoglobulins and skin and nasal provocation tests to grass pollen.
RESULTS
A total of 36 patients were included. Log
CONCLUSIONS
ILIT gives a substantial reduction in grass pollen allergy symptoms and use of rescue medication, significant in the first season after treatment. A booster injection had no additional effect.
Identifiants
pubmed: 32679209
pii: S0091-6749(20)30964-7
doi: 10.1016/j.jaci.2020.07.002
pii:
doi:
Substances chimiques
Allergens
0
Antigens, Plant
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1011-1019Informations de copyright
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.